福尔马林固定石蜡包埋的人乳腺癌中PTEN表达的免疫组织化学检测方案。
Protocol for PTEN expression by immunohistochemistry in formalin-fixed paraffin-embedded human breast carcinoma.
作者信息
Sakr Rita A, Barbashina Violetta, Morrogh Mary, Chandarlapaty Sarat, Andrade Victor P, Arroyo Crispinita D, Olvera Narciso, King Tari A
机构信息
Sloan-Kettering Institute, Department of Surgery, Memorial Sloan-Kettering Cancer Center, New York, NY, USA.
出版信息
Appl Immunohistochem Mol Morphol. 2010 Jul;18(4):371-4. doi: 10.1097/PAI.0b013e3181d50bd5.
Abstract
The PI3K/PTEN pathway plays a major role in carcinogenesis. Dysregulation of this pathway occurs frequently in breast cancer, and loss of PTEN expression is emerging as a potentially important mechanism of resistance to the widely used anti-HER2 therapy, trastuzumab. However, assays for loss of PTEN expression have suffered from lack of consistency. Here, we describe an automated and reliable protocol for PTEN protein expression by immunohistochemistry in formalin-fixed paraffin-embedded tissue that can be easily incorporated into clinical trials.
摘要
PI3K/PTEN信号通路在肿瘤发生过程中起主要作用。该信号通路的失调在乳腺癌中频繁发生，PTEN表达缺失正成为对广泛使用的抗HER2疗法曲妥珠单抗产生耐药性的一个潜在重要机制。然而，PTEN表达缺失的检测方法一直缺乏一致性。在此，我们描述了一种通过免疫组织化学在福尔马林固定石蜡包埋组织中检测PTEN蛋白表达的自动化且可靠的方案，该方案可轻松纳入临床试验。
相似文献
1
Protocol for PTEN expression by immunohistochemistry in formalin-fixed paraffin-embedded human breast carcinoma.
Appl Immunohistochem Mol Morphol. 2010 Jul;18(4):371-4. doi: 10.1097/PAI.0b013e3181d50bd5.
2
Pathologic scoring of PTEN immunohistochemistry in endometrial carcinoma is highly reproducible.
Int J Gynecol Pathol. 2012 Jan;31(1):48-56. doi: 10.1097/PGP.0b013e3182230d00.
3
A gene-protein assay for human epidermal growth factor receptor 2 (HER2): brightfield tricolor visualization of HER2 protein, the HER2 gene, and chromosome 17 centromere (CEN17) in formalin-fixed, paraffin-embedded breast cancer tissue sections.
Diagn Pathol. 2012 May 30;7:60. doi: 10.1186/1746-1596-7-60.
4
A robust immunohistochemical assay for detecting PTEN expression in human tumors.
Appl Immunohistochem Mol Morphol. 2011 Mar;19(2):173-83. doi: 10.1097/PAI.0b013e3181f1da13.
5
Reliable LC3 and p62 autophagy marker detection in formalin fixed paraffin embedded human tissue by immunohistochemistry.
Eur J Histochem. 2015 May 5;59(2):2481. doi: 10.4081/ejh.2015.2481.
6
Droplet digital polymerase chain reaction detection of HER2 amplification in formalin fixed paraffin embedded breast and gastric carcinoma samples.
Exp Mol Pathol. 2016 Apr;100(2):287-93. doi: 10.1016/j.yexmp.2015.11.027. Epub 2015 Nov 25.
7
A novel quantitative immunohistochemistry method for precise protein measurements directly in formalin-fixed, paraffin-embedded specimens: analytical performance measuring HER2.
Mod Pathol. 2017 Feb;30(2):180-193. doi: 10.1038/modpathol.2016.176. Epub 2016 Oct 21.
8
PTEN loss is a predictive marker for HER2-positive metastatic breast cancer patients treated with trastuzumab-based therapies.
J BUON. 2019 Sep-Oct;24(5):1920-1926.
9
Evaluation of the association of PIK3CA mutations and PTEN loss with efficacy of trastuzumab therapy in metastatic breast cancer.
Breast Cancer Res Treat. 2011 Jul;128(2):447-56. doi: 10.1007/s10549-011-1572-5. Epub 2011 May 19.
10
PTEN protein loss by immunostaining: analytic validation and prognostic indicator for a high risk surgical cohort of prostate cancer patients.
Clin Cancer Res. 2011 Oct 15;17(20):6563-73. doi: 10.1158/1078-0432.CCR-11-1244. Epub 2011 Aug 30.
引用本文的文献
1
Immunohistochemistry for PTEN testing in HR +/HER2- metastatic breast cancer.
Virchows Arch. 2025 Sep 11. doi: 10.1007/s00428-025-04249-5.
2
INPP5A phosphatase is a synthetic lethal target in GNAQ and GNA11-mutant melanomas.
Nat Cancer. 2024 Mar;5(3):481-499. doi: 10.1038/s43018-023-00710-z. Epub 2024 Jan 17.
3
Inhibition of ubiquitin specific peptidase 8 is effective against 5-fluorouracil resistance in colon cancer via suppressing EGFR and EGFR-mediated signaling pathways.
Histol Histopathol. 2024 Feb;39(2):251-261. doi: 10.14670/HH-18-629. Epub 2023 May 17.
4
The impact of PIK3CA mutations and PTEN expression on the effect of neoadjuvant therapy for postmenopausal luminal breast cancer patients.
BMC Cancer. 2023 Apr 27;23(1):384. doi: 10.1186/s12885-023-10853-y.
5
Reducing N6AMT1-mediated 6mA DNA modification promotes breast tumor progression via transcriptional repressing cell cycle inhibitors.
Cell Death Dis. 2022 Mar 7;13(3):216. doi: 10.1038/s41419-022-04661-8.
6
The Role of the EZH2 and H3K27me3 Expression as a Predictor of Clinical Outcomes in Salivary Duct Carcinoma Patients: A Large-Series Study With Emphasis on the Relevance to the Combined Androgen Blockade and HER2-Targeted Therapy.
Front Oncol. 2022 Feb 3;11:779882. doi: 10.3389/fonc.2021.779882. eCollection 2021.
7
Combined analysis of PTEN, HER2, and hormone receptors status: remodeling breast cancer risk profiling.
BMC Cancer. 2021 Oct 28;21(1):1152. doi: 10.1186/s12885-021-08889-z.
8
PTEN Expression as a Complementary Biomarker for Mismatch Repair Testing in Breast Cancer.
Int J Mol Sci. 2020 Feb 21;21(4):1461. doi: 10.3390/ijms21041461.
9
The role of mammalian target of rapamycin pathway in the pathogenesis of pauci-immune glomerulonephritis.
Ren Fail. 2019 Nov;41(1):907-913. doi: 10.1080/0886022X.2019.1667829.
10
Precise Immunodetection of PTEN Protein in Human Neoplasia.
Cold Spring Harb Perspect Med. 2019 Dec 2;9(12):a036293. doi: 10.1101/cshperspect.a036293.
本文引用的文献
1
Systems biology reveals new strategies for personalizing cancer medicine and confirms the role of PTEN in resistance to trastuzumab.
Cancer Res. 2009 Aug 15;69(16):6713-20. doi: 10.1158/0008-5472.CAN-09-0777. Epub 2009 Jul 28.
2
Reduced expression of PTEN protein and its prognostic implications in invasive ductal carcinoma of the breast.
Oncology. 2005;68(4-6):398-404. doi: 10.1159/000086981. Epub 2005 Jul 12.
3
Antibody-based profiling of the phosphoinositide 3-kinase pathway in clinical prostate cancer.
Clin Cancer Res. 2004 Dec 15;10(24):8351-6. doi: 10.1158/1078-0432.CCR-04-0130.
4
PTEN activation contributes to tumor inhibition by trastuzumab, and loss of PTEN predicts trastuzumab resistance in patients.
Cancer Cell. 2004 Aug;6(2):117-27. doi: 10.1016/j.ccr.2004.06.022.
5
Promoter methylation of the PTEN gene is a common molecular change in breast cancer.
Genes Chromosomes Cancer. 2004 Oct;41(2):117-24. doi: 10.1002/gcc.20062.
6
Human cancer, PTEN and the PI-3 kinase pathway.
Semin Cell Dev Biol. 2004 Apr;15(2):171-6. doi: 10.1016/j.semcdb.2003.12.021.
7
Reduced expression of PTEN correlates with breast cancer progression.
Hum Pathol. 2002 Apr;33(4):405-9. doi: 10.1053/hupa.2002.124721.
8
Loss of PTEN expression as a prognostic marker for tongue cancer.
Arch Otolaryngol Head Neck Surg. 2001 Dec;127(12):1441-5. doi: 10.1001/archotol.127.12.1441.
9
Immunohistochemical evidence of loss of PTEN expression in primary ductal adenocarcinomas of the breast.
Am J Pathol. 1999 Oct;155(4):1253-60. doi: 10.1016/S0002-9440(10)65227-3.
10
Mutation analysis of the putative tumor suppressor gene PTEN/MMAC1 in primary breast carcinomas.
Cancer Res. 1997 Sep 1;57(17):3657-9.
Zotero 插件